EU/1/16/1110/001 |
3820C |
Chenodeoxycholic acid Leadiant 250 mg tvrdé kapsuly |
cps dur 100x250 mg (PVC/Al) |
LEI |
10.04.2022 |
EU/1/16/1087/001 |
8955B |
Coagadex 250 IU, prášok a rozpúš?adlo na injek?ný roztok |
plv iol 1x250 IU + 2,5 ml solv. (liek.inj.skl.+prenos.zar.) |
BPO |
16.03.2021 |
EU/1/16/1087/002 |
8956B |
Coagadex 500 IU, prášok a rozpúš?adlo na injek?ný roztok. |
plv iol 1x500 IU + 5 ml solv. (liek.inj.skl.+prenos.zar.) |
BPO |
16.03.2021 |
EU/1/13/890/004 |
1301B |
COMETRIQ 20 mg tvrdé kapsuly |
cps dur 84x20 mg (blis.PVC/PE/PCTFE-Al) |
IAA-1 |
26.03.2019 |
EU/1/13/890/001 |
9744A |
COMETRIQ 20 mg tvrdé kapsuly |
cps dur 21x20 mg (blis.PVC/PE/PCTFE-Al) |
IAA-1 |
26.03.2019 |
EU/1/13/890/006 |
1303B |
COMETRIQ 20 mg tvrdé kapsuly, COMETRIQ 80 mg tvrdé kapsuly |
cps dur 84x20 mg + 28x80 mg (blis.PVC/PE/PCTFE-Al) |
IAA-1 |
26.03.2019 |
EU/1/13/890/005 |
1302B |
COMETRIQ 20 mg tvrdé kapsuly, COMETRIQ 80 mg tvrdé kapsuly |
cps dur 28x20 mg + 28x80 mg (blis.PVC/PE/PCTFE-Al) |
IAA-1 |
26.03.2019 |
EU/1/13/890/003 |
9746A |
COMETRIQ 20 mg tvrdé kapsuly, COMETRIQ 80 mg tvrdé kapsuly |
cps dur 21x20 mg + 7x80 mg (blis.PVC/PE/PCTFE-Al) |
IAA-1 |
26.03.2019 |
EU/1/13/890/002 |
9745A |
COMETRIQ 20 mg tvrdé kapsuly, COMETRIQ 80 mg tvrdé kapsuly |
cps dur 7x20 mg + 7x80 mg (blis.PVC/PE/PCTFE-Al) |
IAA-1 |
26.03.2019 |
EU/1/15/1036/002 |
6527B |
CRESEMBA 100 mg tvrdé kapsuly |
cps dur 14x100 mg (blis.Al/Al) |
BSL-GB-1 |
15.10.2020 |
EU/1/15/1036/001 |
6526B |
CRESEMBA 200 mg prášok na prípravu infúzneho koncentrátu |
plc ifc 1x200 mg (liek.inj.skl.) |
BSL-GB-1 |
15.10.2020 |
EU/1/17/1262/001 |
7442C |
CRYSVITA 10 mg injek?ný roztok |
sol inj 1x1 ml/10 mg (liek.inj.skl.) |
KWH-NL |
19.02.2019 |
EU/1/17/1262/002 |
7443C |
CRYSVITA 20 mg injek?ný roztok |
sol inj 1x1 ml/20 mg (liek.inj.skl.) |
KWH-NL |
19.02.2019 |
EU/1/17/1262/003 |
7444C |
CRYSVITA 30 mg injek?ný roztok |
sol inj 1x1 ml/30 mg (liek.inj.skl.) |
KWH-NL |
19.02.2019 |
EU/1/15/1049/001 |
3071C |
Cystadrops, 3,8 mg/ml o?ná roztoková instilácia |
int opo 1x5 ml/19 mg (liek.skl.) |
OEU-1 |
19.01.2022 |
EU/1/12/792/001 |
2969A |
Dacogen 50 mg prášok na prípravu infúzneho koncentrátu |
plc ifc 1x50 mg (liek.skl.) |
JNS |
|
EU/1/16/1101/002 |
9489B |
DARZALEX 20 mg/ml koncentrát na infúzny roztok |
con inf 1x20 ml/400 mg (liek.inj.skl.) |
JNS |
24.05.2018 |
EU/1/16/1101/001 |
9488B |
DARZALEX 20 mg/ml koncentrát na infúzny roztok |
con inf 1x5 ml/100 mg (liek.inj.skl.) |
JNS |
24.05.2018 |
EU/1/13/878/001 |
7772A |
Defitelio 80 mg/ml infúzny koncentrát |
con inf 10x2,5 ml/200 mg (liek.inj.skl.) |
GTI |
22.10.2023 |
EU/1/13/875/004 |
4246B |
Deltyba 50 mg filmom obalené tablety |
tbl flm 48x50 mg (blis.Al/Al) |
OTN |
30.04.2019 |
EU/1/11/667/021 |
7920C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 180x267 mg (f?.HDPE) |
HLR-DE |
|
EU/1/11/667/020 |
7919C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 42x267 mg (f?.HDPE) |
HLR-DE |
|
EU/1/11/667/008 |
3954C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 180 (2x90)x267 mg (f?.HDPE) |
HLR-DE |
|
EU/1/11/667/007 |
3953C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 90x267 mg (f?.HDPE) |
HLR-DE |
|
EU/1/11/667/006 |
3952C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 42 (2x21)x267 mg (f?.HDPE) |
HLR-DE |
|
EU/1/11/667/005 |
3951C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 21x267 mg (f?.HDPE) |
HLR-DE |
|
EU/1/11/667/017 |
4591C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 252 [3 (4x21)]x267 mg (blis.PVC/Aclar/PCTFE) |
HLR-DE |
|
EU/1/11/667/016 |
4590C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 63 (1x21 a 2x21)x267 mg (blis.PVC/Aclar/PCTFE) |
HLR-DE |
|
EU/1/11/667/015 |
4586C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 168 (8x21)x267 mg (blis.PVC/Aclar/PCTFE) |
HLR-DE |
|
EU/1/11/667/014 |
4584C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 84 (4x21)x267 mg (blis.PVC/Aclar/PCTFE) |
HLR-DE |
|
EU/1/11/667/013 |
4583C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 42 (2x21)x267 mg (blis.PVC/Aclar/PCTFE) |
HLR-DE |
|
EU/1/11/667/012 |
4582C |
Esbriet 267 mg filmom obalené tablety |
tbl flm 21 (1x21)x267 mg (blis.PVC/Aclar/PCTFE) |
HLR-DE |
|
EU/1/11/667/003 |
06330 |
Esbriet 267 mg tvrdé kapsuly |
cps dur 270x267 mg (f?.HDPE) |
HLR-DE |
|
EU/1/11/667/002 |
06329 |
Esbriet 267 mg tvrdé kapsuly |
cps dur 252x1x267 mg (blis.PVC/PE/PCTFE/Al-jednotk.bal.) |
HLR-DE |
|
EU/1/11/667/001 |
06324 |
Esbriet 267 mg tvrdé kapsuly |
cps dur 63 (7x3+7x6)x267 mg (blis.PVC/PE/PCTFE/Al) |
HLR-DE |
|
EU/1/11/667/010 |
3956C |
Esbriet 534 mg filmom obalené tablety |
tbl flm 90x534 mg (f?.HDPE) |
HLR-DE |
|
EU/1/11/667/009 |
3955C |
Esbriet 534 mg filmom obalené tablety |
tbl flm 21x534 mg (f?.HDPE) |
HLR-DE |
|
EU/1/11/667/011 |
3957C |
Esbriet 801 mg filmom obalené tablety |
tbl flm 90x801 mg (f?.HDPE) |
HLR-DE |
|
EU/1/11/667/019 |
4593C |
Esbriet 801 mg filmom obalené tablety |
tbl flm 252 [3 (4x21)]x801 mg (blis.PVC/Aclar/PCTFE) |
HLR-DE |
|
EU/1/11/667/018 |
4592C |
Esbriet 801 mg filmom obalené tablety |
tbl flm 84 (4x21)x801 mg (blis.PVC/Aclar/PCTFE) |
HLR-DE |
|
EU/1/15/1023/003 |
5853B |
Farydak 10 mg tvrdé kapsuly |
cps dur 24x10 mg (blis.PVC/PCTFE/Al) |
NEH-IE |
28.08.2020 |
EU/1/15/1023/002 |
5848B |
Farydak 10 mg tvrdé kapsuly |
cps dur 12x10 mg (blis.PVC/PCTFE/Al) |
NEH-IE |
28.08.2020 |
EU/1/15/1023/001 |
5846B |
Farydak 10 mg tvrdé kapsuly |
cps dur 6x10 mg (blis.PVC/PCTFE/Al) |
NEH-IE |
28.08.2020 |
EU/1/15/1023/006 |
5856B |
Farydak 15 mg tvrdé kapsuly |
cps dur 24x15 mg (blis.PVC/PCTFE/Al) |
NEH-IE |
28.08.2020 |
EU/1/15/1023/005 |
5855B |
Farydak 15 mg tvrdé kapsuly |
cps dur 12x15 mg (blis.PVC/PCTFE/Al) |
NEH-IE |
28.08.2020 |
EU/1/15/1023/004 |
5854B |
Farydak 15 mg tvrdé kapsuly |
cps dur 6x15 mg (blis.PVC/PCTFE/Al) |
NEH-IE |
28.08.2020 |
EU/1/15/1023/009 |
5865B |
Farydak 20 mg tvrdé kapsuly |
cps dur 24x20 mg (blis.PVC/PCTFE/Al) |
NEH-IE |
28.08.2020 |
EU/1/15/1023/008 |
5864B |
Farydak 20 mg tvrdé kapsuly |
cps dur 12x20 mg (blis.PVC/PCTFE/Al) |
NEH-IE |
28.08.2020 |
EU/1/15/1023/007 |
5860B |
Farydak 20 mg tvrdé kapsuly |
cps dur 6x20 mg (blis.PVC/PCTFE/Al) |
NEH-IE |
28.08.2020 |
EU/1/08/461/002 |
07730 |
Firazyr 30 mg injek?ný roztok v naplnenej injek?nej strieka?ke |
sol inj 3x3 ml/30 mg (striek.skl.napln.) |
SHP-IE-1 |
|